Serial No.: 10/635,108 Filing Date: August 5, 2003

Amendment and Reply to Nonfinal Office Action

September 27, 2004

Page 4 of 17

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1.-8. (canceled)

- 9. (currently amended) A method for inhibiting [[a]] an mRNA, comprising:
- a) providing an interfering hairpin RNA having comprising the structure X_1 -L- X_2 , wherein X_1 and X_2 are nucleotide sequences having sufficient complementarity to one another to form a double-stranded stem hybrid and L is a <u>flexible</u> loop region comprising a non-nucleotide linker molecule <u>of 10-24 atoms in length</u>, wherein at least a portion of one of the nucleotide sequences located within the double-stranded stem is complementary to a sequence of <u>said the</u> target mRNA; and
- b) contacting shRNA the RNA comprising the structure X_1 -L- X_2 with a sample containing or suspected of containing the target mRNA under conditions that favor intermolecular hybridization between transfection of the shRNA RNA comprising the structure X_1 -L- X_2 into a cell comprising the target mRNA and the target mRNA whereby presence of the shRNA RNA comprising the structure X_1 -L- X_2 decreases expression of the target mRNA[[.]];

wherein X_1 and X_2 each independently comprise between about 19 to 27 nucleotides, and L comprises a polyether, a polyamine, a polyester, a polyphosphodiester, an alkylene, or a combination thereof.

- 10. (currently amended) A method for assaying whether a gene product is a suitable target for drug discovery comprising:
- a) introducing an [[sh]]RNA which targets the \underline{an} mRNA of the \underline{a} gene for degradation into a cell or organism, wherein said [[sh]]RNA having comprises the structure X_1 -L- X_2 , wherein X_1 and X_2 are nucleotide sequences having sufficient complementarity to

Serial No.: 10/635,108 Filing Date: August 5, 2003

Amendment and Reply to Nonfinal Office Action

September 27, 2004

Page 5 of 17

one another to form a double-stranded stem hybrid and L is a <u>flexible</u> loop region comprising a non-nucleotide linker molecule <u>of 10-24 atoms in length</u>, wherein at least a portion of one of the nucleotide sequences located within the double-stranded stem <u>hybrid</u> is complementary to a sequence of said double-stranded RNA <u>mRNA</u>, wherein X_1 and X_2 each independently comprise between about 19 to 27 nucleotides, and L comprises a polyether, a polyamine, a polyester, a polyphosphodiester, an alkylene, or a combination thereof;

- b) maintaining the cell or organism of [[(]]a) under conditions in which degradation of the mRNA occurs, resulting in decreased expression of the gene; and
- c) determining the effect of the decreased expression of the gene on the cell or organism, wherein if decreased expression has an effect, then the gene product is a target for drug discovery.

Please add the following new claims:

- 11. (New) The method according to claim 9, wherein L is a polyether and the polyether comprises a polyethylene glycol, a polyalcohol, a propylene glycol, or a combination thereof.
- 12. (New) The method according to claim 9, wherein the RNA comprising the structure X_1 -L- X_2 comprises an overhang.
- 13. (New) The method according to claim 12, wherein the overhang comprises 1 to 5 nucleotides.
- 14. (New) The method according to claim 13, wherein the overhang is a 3' overhang.
- 15. (New) The method according to claim 13, wherein the overhang is a 5' overhang:
- 16. (New) The method according to claim 9, wherein the RNA comprising the structure X_1 -L- X_2 comprises a left hairpin.

Serial No.: 10/635,108 Filing Date: August 5, 2003

Amendment and Reply to Nonfinal Office Action

September 27, 2004

Page 6 of 17

17. (New) The method according to claim 9, wherein the RNA comprising the structure X_1 -L- X_2 comprises a right hairpin.

18. (New) The method according to claim 9, wherein the RNA comprising the structure X_1 -L- X_2 comprises a bulge.

19. (New) The method according to claim 18, wherein the bulge is a stem loop bulge.

20. (New) The method according to claim 18, wherein the bulge comprises a single uridine residue opposing double uridine residues.

21. (New) The method according to claim 9, wherein X_1 or X_2 is 100% complementary to the target mRNA.

22. (New) The method according to claim 9, wherein L is covalently attached to X_1 and to X_2 via an ether, an ester, a carbamate, a phosphate ester, or an amine linkage.

23. (New) A method for inhibiting a target mRNA, comprising:

a) providing an RNA comprising the structure X_1 -L- X_2 , wherein X_1 and X_2 are nucleotide sequences having sufficient complementarity to one another to form a double-stranded stem hybrid and L is a loop region comprising a non-nucleotide linker molecule, wherein at least a portion of one of the nucleotide sequences located within the double-stranded stem is complementary to a sequence of the target mRNA; and

b) contacting the RNA comprising the structure X_1 -L- X_2 with a sample containing or suspected of containing the target mRNA under conditions that favor transfection of the RNA comprising the structure X_1 -L- X_2 into a cell comprising the target mRNA whereby presence of the RNA comprising the structure X_1 -L- X_2 decreases expression of the target mRNA;

Serial No.: 10/635,108 Filing Date: August 5, 2003

Amendment and Reply to Nonfinal Office Action

September 27, 2004

Page 7 of 17

wherein X_1 and X_2 each independently comprise between about 19 to 27 nucleotides; L comprises a polyether, a polyamine, a polyester, a polyphosphodiester, an alkylene, or a combination thereof; L is 10-24 atoms in length; the RNA comprising the structure X_1 -L- X_2 comprises a left hairpin RNA; and the left hairpin RNA comprising the structure X_1 -L- X_2 comprises an overhang of 1 to 5 nucleotides and at least one bulge.